Evidence-Based Diuretic Therapy for Improving Cardiovascular Prognosis in Systemic Hypertension Article

Full Text via DOI: 10.1016/j.amjcard.2010.12.016 PMID: 21316640 Web of Science: 000289702400013

Cited authors

  • Al Badarin, Firas J.; Abuannadi, Mohammad A.; Lavie, Carl J.; O'Keefe, James H.


  • Diuretics are among the most commonly prescribed cardiovascular (CV) medications. The strength of evidence supporting the effectiveness of diuretics in lowering blood pressure and for preventing major adverse CV events in patients with hypertension varies considerably among diuretic classes and even among agents within the same class. Unfortunately, common prescribing habits among American physicians, including specialists in CV diseases, are not in line with the existing evidence regarding diuretic therapy for improving CV prognosis. In conclusion, although hydrochlorothiazide is the standard diuretic used for hypertension, the outcomes data suggest that chlorthalidone, indapamide, and possibly even the aldosterone receptor blockers (spironolactone and eplerenone) may be superior agents. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1178-1184)

Publication date

  • 2011

Published in

International Standard Serial Number (ISSN)

  • 0002-9149

Start page

  • 1178

End page

  • 1184


  • 107


  • 8